Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease

INCLUSION CRITERIA: 1. Males or Females, 45 - 80 years of age 2. Confirmed coronary artery disease defined as one of the following: * Post-acute coronary syndrome or myocardial infarction or * Post percutaneous coronary intervention or coronary artery bypass graft or oAngina pectoris with documented (electrocardiogram or imaging study) ischemia or * Angiographically documented lesion occluding ≥70% of a coronary vessel And at high risk as defined as one or more of the following: * Elevated hsCRP (high-sensitivity C-reactive protein) * Diabetes mellitus * History of carotid artery disease and/or peripheral artery disease * Thrombo-embolic transient ischemic attack or stroke \>1 year prior to screening 3. All subjects must be receiving low dose aspirin and/or clopidogrel and/or ticlopidine. EXCLUSION CRITERIA 1. History of acquired or congenital bleeding disorder, coagulopathy or platelet disorder, or history of pathological bleeding within the last 6 months 2. History of intracranial bleeding, history of hemorrhagic retinopathy or known structural cerebral vascular lesion 3. Clinically significant hematological, hepatic or renal abnormalities 4. Patients with some specific ST-segment changes, severe congestive heart failure or uncontrolled cardiac arrhythmias at baseline 5. Recent significant (as determined by the investigator) cardiovascular events